Bristol Myers Squibb (CELG-RI) Change in Receivables (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Change in Receivables of $1.2 billion for Q2 2026, up 144.42% year-over-year from $484.0 million in Q2 2025, and up 170.12% quarter-over-quarter from -$1.7 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Change in Receivables (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Change in Receivables for 18 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Receivables rose 144.42% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at -$678.0 million (down 102.39% YoY), while the FY2025 annual figure was $295.0 million, up 211.74% from the prior year.
- Change in Receivables grew to $1.2 billion in Q2 2026 per CELG-RI's latest filing, from -$1.7 billion in the prior quarter.
- Across five years, Change in Receivables topped out at $1.2 billion in Q2 2026 and bottomed at -$1.7 billion in Q1 2026.
- Historically, Change in Receivables has averaged $65.8 million across 5 years, with a median of $85.5 million in 2022.
- Annual changes were most pronounced in 2024 — Change in Receivables soared 1467.69% — and 2026, when it slumped 11146.67%.
- Bristol Myers Squibb's Change in Receivables stood at $106.0 million in 2022, then surged by 379.25% to $508.0 million in 2023, then slumped by 128.15% to -$143.0 million in 2024, then soared by 86.71% to -$19.0 million in 2025, then surged by 6326.32% to $1.2 billion in 2026.
- Business Quant data shows CELG-RI's Change in Receivables at $1.2 billion in Q2 2026, -$1.7 billion in Q1 2026, and -$19.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 1.18 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Bn |
| Jun 30, 2026 | 1.18 Bn |
| Mar 31, 2026 | -1.69 Bn |
| Mar 31, 2026 | -1.69 Bn |
| Dec 31, 2025 | -19.00 Mn |
| Dec 31, 2025 | -19.00 Mn |
| Sep 30, 2025 | -155.00 Mn |
| Sep 30, 2025 | -155.00 Mn |
| Jun 30, 2025 | 484.00 Mn |
| Jun 30, 2025 | 484.00 Mn |
| Mar 31, 2025 | -15.00 Mn |
| Mar 31, 2025 | -15.00 Mn |
| Dec 31, 2024 | -143.00 Mn |
| Dec 31, 2024 | -143.00 Mn |
| Sep 30, 2024 | -661.00 Mn |
| Sep 30, 2024 | -661.00 Mn |
| Jun 30, 2024 | 1.02 Bn |
| Jun 30, 2024 | 1.02 Bn |
| Mar 31, 2024 | -479.00 Mn |
| Mar 31, 2024 | -479.00 Mn |